FARE - Food Allergy Research & Education Logo

FARE Blog

On Saturday, April 13, food allergy investigators and patient advocates came together in McLean, VA, for the Seventh Annual FARE Research Retreat. The gathering included 120 clinicians, industry representatives, scientists in academia and public service, and directors from the 33 Centers of Excellence in the FARE Clinical Network. Together, they shared experimental findings and explored new opportunities to fulfill FARE’s mission: to improve the quality of life and health for patients with food allergy and provide hope through the promise of new treatments.

Robert M. Anthony, PhD, is an associate professor at Harvard Medical School and a principal investigator in the Center for Immunology and Inflammatory Diseases at Massachusetts General Hospital. He received a mid-career FARE Investigator in Food Allergy award in 2017. Here he discusses his research on how the glycosylation of allergy-associated IgE antibodies – that is, the addition of sugars molecules to IgE proteins – might influence food allergy.

Recognizing March as National Nutrition Month, this guest post by Teen Advisory Group (TAG) member and cookbook author Catherine Walker encourages food allergy patients and families to get creative in the kitchen with wholesome, allergy-friendly meals. You can hear more from Catherine in this month’s FARE+Well newsletter.

Stephanie Eisenbarth, MD, PhD, is an associate professor of Laboratory Medicine, of Immunobiology and of Medicine (Immunology) at Yale School of Medicine. She received a 2017 Mid-Career FARE Investigator in Food Allergy Award for her research on a rare, inherited sensitivity to food allergens that could shed light on the mechanisms of food allergies in the wider population.

At last weekend’s annual scientific meeting of the American Academy of Allergy, Asthma & Immunology, Aimmune Therapeutics and DBV Technologies presented updates on the two immunotherapies for peanut allergy that have progressed farthest in the U.S. Food and Drug Administration’s approval process for bringing new drugs to market. Yesterday, we posted on the FARE Blog some of the data reported by Aimmune. Here, we present findings released by DBV.

At last weekend’s annual scientific meeting of the American Academy of Allergy, Asthma & Immunology, Aimmune Therapeutics and DBV Technologies presented updates on the two immunotherapy approaches for peanut allergy that have progressed farthest in the U.S. Food and Drug Administration’s approval process for bringing new drugs to market.

Report from AAAAI 2019

This weekend’s annual scientific meeting of the American Academy of Allergy, Asthma & Immunology features hundreds of research presentations, many of which provide noteworthy new findings in the field of food allergy. FARE staff are attending the San Francisco conference along with thousands of allergists, immunologists, researchers and other healthcare providers. Here are highlights from some of Sunday’s presentations in the field of food allergy.

Report from AAAAI 2019

This weekend’s annual scientific meeting of the American Academy of Allergy, Asthma & Immunology features hundreds of research presentations, many of which provide noteworthy new findings in the field of food allergy. FARE staff are attending the San Francisco conference along with thousands of allergists, immunologists, researchers and other healthcare providers. Here are highlights from some of Saturday’s presentations focusing on the food allergy field.

Last month, researchers at Stanford University published a study that shed new light on blood cells that play an essential role in peanut allergy. These very rare IgE B cells make peanut-specific IgE antibodies that, when bound to peanut protein, can trigger the release of histamines and other molecules that cause reaction symptoms.

Two recently released large-scale studies of food allergy prevalence have resulted in an update of FARE’s frequently cited statistics that provide estimates on how many people are living with this potentially life-threatening disease.

We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies.